JAGX 8-K SEC Filing Analysis

Latest settled — T+20d

JAGX ▼ -77.35% at T+20d

SHORT call ✓ call won +77.35% · α vs SPY +87.13% · entry $14.35 → $3.25

Next anchor: T+60d in 17d

Last close $2.69 (close Jun 12) · +81.25% from $14.35 entry (call sign-flipped)

Entry anchored
Apr 6, 03:59 PM ET
via Databento tick

T+1d

-97.22%

call +97.22% · α +99.76%

$0.3990

settled 2mo ago

T+5d

-97.17%

call +97.17% · α +102.50%

$0.4060

settled 2mo ago

T+20d

-77.35%

call +77.35% · α +87.13%

$3.25

settled 6w ago

T+60d

—

call — · α —

—

in 17d

Price Chart

Loading chart...

Executive Summary

Jaguar Health reported 2025 financial results showing a 5% sequential increase in Q4 2025 revenue to $3.2M, but an 8% decline year-over-year. The company announced a $16M non-dilutive licensing deal with Future Pak and faces a Nasdaq listing compliance issue under appeal. Net loss widened to $53.6M from $38.5M in 2024.

Actionable Insight

The stock may react negatively to widening losses and Nasdaq compliance risks despite the licensing deal. Monitor the April 7 hearing outcome and future revenue trends under the new licensing structure with Future Pak.

Key Facts

Q4 2025 net revenue: $3.2M, up 5% QoQ but down 8% YoY from $3.5M
2025 total net revenue: $11.5M, down 1.5% from $11.7M in 2024
Net loss attributable to common shareholders: $53.6M in 2025 vs $38.5M in 2024
Received $16M upfront payment from Future Pak licensing deal in January 2025
Nasdaq issued non-compliance determination on March 5, 2026 for minimum bid price, hearing scheduled for April 7, 2026
Impairment loss of $0.8M on intangible assets due to delays in IBS and PEDS programs

Financial Impact

Revenue declined 1.5% year-over-year to $11.5M while net loss increased by $15.1M to $53.6M, with a $0.8M impairment charge

revenuenet lossimpairmentR&D expenses

Risk Factors

Nasdaq delisting risk pending hearing decision
Continued revenue decline and increasing losses
Dependence on future milestone payments from licensing deal

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-144604
Document: d111491d8k.htm	0001193125-26-144604
Document: 0001193125-26-144604-index-headers.html	0001193125-26-144604
Document: 0001193125-26-144604-index.html	0001193125-26-144604
Document: 0001193125-26-144604.txt	0001193125-26-144604
8-K Data (Synthetic)	0001193125-26-144604

12 reports for JAGX

T+1T+5T+20T+60

50% Hit rate 2 of 4 directional calls best @ T+1▲ +97.54%Apr 27, 2026

Filters

Reports for JAGX — sortable, filterable
	Type				Now
Jun 11, 2026 3d ago	8-K BEARISH ★ 8/10	$2.74 awaiting T+1	awaiting T+1	—	$2.69 (+1.82%)
Jun 8, 2026 6d ago	8-K NEUTRAL ★ 5/10	$2.60 awaiting T+1	awaiting T+1	—	$2.69 (+3.66%)
Jun 2, 2026 12d ago	8-K BEARISH ★ 6/10	$2.92 $3.05	▼ −4.45%	▼ −4.05%	$2.69 (+7.88%)
May 29, 2026 16d ago	DEFA14A NEUTRAL ★ 4/10	$3.27 $3.22	▼ −1.53%	▼ −1.67%	$2.69 (−17.74%)
May 27, 2026 18d ago	8-K NEUTRAL ★ 4/10	$3.19 $3.29	▲ +3.13%	▲ +2.58%	$2.69 (−15.67%)
May 22, 2026 23d ago	8-K BEARISH ★ 6/10	$3.11 $3.19	▼ −2.57%	▼ −2.56%	$2.69 (+13.50%)
May 19, 2026 26d ago	8-K MIXED ★ 6/10	$3.67 $3.47	▼ −5.45%	▼ −5.64%	$2.69 (−26.70%)
May 6, 2026 5w ago	DEFA14A NEUTRAL ★ 1/10	$2.82 $2.98	▲ +5.67%	▲ +6.00%	$2.69 (−4.61%)
May 4, 2026 5w ago	8-K BEARISH ★ 8/10	$3.25 $3.01	▲ +7.38%	▲ +8.18%	$2.69 (+17.23%)
Apr 27, 2026 6w ago	8-K BEARISH ★ 8/10	$9.80 $0.2410	▲ +97.54%	▲ +97.06%	$2.69 (+72.55%)

US Market Status

Market Closed — Opens in 4h 35m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access